Novo Nordisk, founded in 1923, is a Danish multinational pharmaceutical company specializing in diabetes care. Novo Nordisk’s primary focus is on developing and manufacturing insulin, as well as other products and treatments for diabetes management. The company is known for its commitment to improving the lives of people living with diabetes through innovative therapies, patient education, and advocacy. Novo Nordisk’s portfolio includes a wide range of insulin products, such as NovoRapid, Levemir, and Victoza, as well as devices for insulin delivery. With a global presence, Novo Nordisk operates manufacturing facilities in several countries, ensuring the production and distribution of its life-saving diabetes medications to patients worldwide.